The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MMSI | -12.61% | +70.13% | +11.21% | +1,530% |
| S&P | +16.23% | +94.45% | +14.22% | +1,685% |
Merit Medical Systems, Inc. engages in the manufacture and marketing of proprietary disposable medical devices. It operates through the Cardiovascular and Endoscopy segments. The Cardiovascular segment consists of peripheral intervention, cardiac intervention, interventional oncology and spine, and cardiovascular and critical care product groups. The Endoscopy segment integrates non-vascular stent technology with balloon dilators, inflation devices, guide wires, procedure kits, and other devices that are used by gastroenterologists, endoscopists, pulmonologists, and thoracic and general surgeons. The company was founded by Fred P. Lampropoulos, Darla Gill, Kent W. Stanger, and William Padilla in July 1987 and is headquartered in South Jordan, UT.
Some investors appeared to think that yesterday's sell-off was way overdone.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $381.95M | 13.1% |
| Gross Profit | $184.22M | 14.9% |
| Gross Margin | 48.23% | 0.7% |
| Market Cap | $5.52B | 10.6% |
| Market Cap / Employee | $0.75M | 0.0% |
| Employees | 7.4K | 6.5% |
| Net Income | $32.58M | -8.8% |
| EBITDA | $80.56M | 11.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $343.87M | -46.2% |
| Accounts Receivable | $204.16M | 11.9% |
| Inventory | 323.3 | 8.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $810.29M | -5.7% |
| Short Term Debt | $10.26M | -12.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 4.81% | -0.8% |
| Return On Invested Capital | 3.67% | 1.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $69.56M | 20.2% |
| Operating Free Cash Flow | $83.31M | 21.6% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 48.41 | 47.66 | 51.84 | 47.49 | 10.86% |
| Price to Book | 4.35 | 4.26 | 4.50 | 3.87 | -3.99% |
| Price to Sales | 4.45 | 4.33 | 4.67 | 3.96 | 1.89% |
| Price to Tangible Book Value | 10.44 | 10.21 | 14.87 | 11.38 | 23.37% |
| Price to Free Cash Flow TTM | 33.53 | 31.58 | 35.86 | 29.46 | 5.04% |
| Enterprise Value to EBITDA | 93.91 | 87.40 | 83.06 | 76.25 | 4.68% |
| Free Cash Flow Yield | 3.0% | 3.2% | 2.8% | 3.4% | -4.80% |
| Return on Equity | 9.4% | 9.3% | 9.2% | 8.6% | -8.97% |
| Total Debt | $819.15M | $794.67M | $817.66M | $820.55M | -5.80% |
MMSI earnings call for the period ending September 30, 2021.
MMSI earnings call for the period ending June 30, 2021.
MMSI earnings call for the period ending March 31, 2021.
MMSI earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
